4.5 Article

New next-generation microwave thermosphere ablation for small hepatocellular carcinoma

Journal

CLINICAL AND MOLECULAR HEPATOLOGY
Volume 27, Issue 4, Pages 564-574

Publisher

KOREAN ASSOC STUDY LIVER
DOI: 10.3350/cmh.2021.0136

Keywords

Carcinoma; Hepatocellular; Radiofrequency ablation; Microwaves

Ask authors/readers for more resources

The study showed that the new generation microwave thermosphere ablation (MTA) could provide safer and more curative treatment for small hepatocellular carcinoma (HCC) in a shorter ablation time compared to radiofrequency ablation (RFA). The MTA group had significantly lower 3-year local tumor progression rate and total complication rate than the RFA group.
Background/Aims: In July 2017, the EmprintTM next-generation microwave ablation system using thermosphere technology (Covidien, Boulder, CO, USA) was approved for use in Japan. This system can produce a predictable spherical ablation zone at higher temperatures than radiofrequency ablation (RFA). The aim of the present study was to elucidate whether this new microwave thermosphere ablation (MTA) could safely improve outcome compared to RFA, which is the standard of care for small hepatocellular carcinoma (HCC). Methods: This retrospective study analyzed 513 patients with 630 HCCs (<= 3 cm) who were performed by percutaneous RFA (174 patients, 214 HCCs) or MTA (339 patients, 416 HCCs) between January 2016 and March 2020. Results: Median ablation time was significantly shorter for MTA (240 seconds) than for RFA (721 seconds; P<0.001). A significant difference in 3-year local tumor progression rate was evident between the RFA group (22%) and MTA group (8%; P<0.001). Multivariable analysis revealed ablation procedure and tumor diameter as independent factors contributing to local tumor progression (MTA; P<0.001; hazard ratio, 0.565; 95% confidence interval, 0.437-0.731). In patients with primary HCC, a significant difference in overall survival was evident (RFA vs. MTA, 3-year, 77% vs. 95%, P=0.029). Ablation procedure and Child-Pugh score were independent factors contributing to survival. The total complication rate was significantly lower for MTA (8%) than for RFA (14%, P<0.05), particularly for bile duct injury (3% vs. 9%, respectively; P<0.05). Conclusions: Next-generation MTA for small HCC could provide safer, more curative treatment in a shorter ablation time than RFA. (Clin Mol Hepatol 2021;27:564-574)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available